In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Small Cap: Bionics to Test Anti-Cancer Drug on Humans (Australia)

This article was originally published in PharmAsia News

Executive Summary

Biotechnology company, Bionomics Limited, will soon initiate clinical trials of a new cancer treatment in Australia. The company's Nov. 22 announcement comes on the heels of the approval of its Investigational New Drug application by the U.S. FDA. The application will also pave the way for further clinical tests of the experimental drug in both Australia and the United States. As a result of the announcement, South Australia-based Bionomics saw its shares rise 7 percent. The new treatment, called BNC105, employs a cancer-fighting method designed to destroy tumors by cutting off their blood supply. BNC105 is just one of Bionomics experimental cancer treatments. In addition to cancer research, the company has also started drug discovery and development programs for multiple sclerosis, anxiety and epilepsy. (Click here for more



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts